<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39216660</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1523-1755</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Kidney international</Title><ISOAbbreviation>Kidney Int</ISOAbbreviation></Journal><ArticleTitle>Chronic endothelial dopamine receptor stimulation improves endothelial function and hemodynamics in autosomal dominant polycystic kidney disease.</ArticleTitle><Pagination><StartPage>1158</StartPage><EndPage>1169</EndPage><MedlinePgn>1158-1169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.kint.2024.08.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0085-2538(24)00626-4</ELocationID><Abstract><AbstractText>Altered polycystin-mediated endothelial flow mechanosensitivity contributes to the development of hypertension and cardiovascular complications in patients with autosomal dominant polycystic kidney disease (ADPKD). Stimulation of endothelial type 5 dopamine receptors (DR5) can acutely compensate for the endothelial consequences of polycystin deficiency, but the chronic impact of this approach must be evaluated in ADPKD. Nineteen patients with ADPKD on standard of care therapy were randomized to receive a 2-month treatment with the DR agonist rotigotine using transdermal patches, nine at 2 mg/24hours and ten at 4 mg/24hours or while ten were untreated. Rotigotine at the dose of 4 mg/24hours significantly increased nitric oxide release (nitrite levels from 10&#xb1;30 to 46&#xb1;34 nmol/L) and radial artery endothelium-dependent flow-mediated dilatation (from 16.4&#xb1;6.3 to 22.5&#xb1;7.3%) in response to hand skin heating. Systemic hemodynamics were not significantly modified but aplanation tonometry showed that rotigotine at 4 mg/24hours reduced aortic augmentation index and pulse pressure without affecting carotid-to femoral pulse wave velocity. Plasma creatinine and urea, urinary cyclic AMP, which contributes to cyst growth in ADPKD and copeptin, a surrogate marker of vasopressin, were not affected by rotigotine. In mice with a specific deletion of polycystin-1 in endothelial cells, chronic infusion of the peripheral DR5 agonist fenoldopam also improved mesenteric artery flow-mediated dilatation and reduced blood pressure. Thus, our study demonstrates that in patients with ADPKD, chronic administration of rotigotine improves conduit artery endothelial function through the restoration of flow-induced nitric oxide release as well as hemodynamics suggesting that endothelial DR5 activation may represent a promising pharmacological approach to prevent cardiovascular complications of ADPKD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dumont</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM) U1096, Endoth&#xe9;lium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France; Department of Pharmacology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France; Centre d'Investigation CLinique-Centre de Ressources Biologiques (CIC-CRB) 1404, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamzaoui</LastName><ForeName>Mouad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groussard</LastName><ForeName>D&#xe9;borah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM) U1096, Endoth&#xe9;lium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacob</LastName><ForeName>Mich&#xe8;le</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remy-Jouet</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM) U1096, Endoth&#xe9;lium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanoy</LastName><ForeName>M&#xe9;lanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Roy</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevalier</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Centre national de la recherche scientifique (CNRS), Institut national des sciences appliqu&#xe9;es (INSA) Rouen Normandie-Normandie Universit&#xe9;-Groupe de Physique des Mat&#xe9;riaux-Unit&#xe9; Mixte de Recherche (GPM-UMR) 6634, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enzensperger</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Friedrich Schiller University Jena, Institute for Organic Chemistry and Macromolecular Chemistry, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arndt</LastName><ForeName>Hans-Dieter</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Friedrich Schiller University Jena, Institute for Organic Chemistry and Macromolecular Chemistry, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renet</LastName><ForeName>Sylvanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM) U1096, Endoth&#xe9;lium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumesnil</LastName><ForeName>Ana&#xef;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM) U1096, Endoth&#xe9;lium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe9;v&#xea;que</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duflot</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM) U1096, Endoth&#xe9;lium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France; Department of Pharmacology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunel</LastName><ForeName>Val&#xe9;ry</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of General Biochemistry, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michel-Despr&#xe9;s</LastName><ForeName>Aurore</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre Hospitalier R&#xe9;gional Universitaire (CHRU) Brest, University Brest, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (Inserm), Unit&#xe9; Mixte de Recherche (UMR) 1078, G&#xe9;n&#xe9;tique, G&#xe9;nomique fonctionnelle et Biotechnologies (GGB), Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Audr&#xe9;zet</LastName><ForeName>Marie-Pierre</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Centre Hospitalier R&#xe9;gional Universitaire (CHRU) Brest, University Brest, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (Inserm), Unit&#xe9; Mixte de Recherche (UMR) 1078, G&#xe9;n&#xe9;tique, G&#xe9;nomique fonctionnelle et Biotechnologies (GGB), Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France; Centre d'Investigation CLinique-Centre de Ressources Biologiques (CIC-CRB) 1404, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joannid&#xe8;s</LastName><ForeName>Robinson</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM) U1096, Endoth&#xe9;lium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France; Department of Pharmacology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerrot</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM) U1096, Endoth&#xe9;lium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France; Centre d'Investigation CLinique-Centre de Ressources Biologiques (CIC-CRB) 1404, Rouen, France; Department of Nephrology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellien</LastName><ForeName>J&#xe9;r&#xe9;my</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM) U1096, Endoth&#xe9;lium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France; Department of Pharmacology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France; Centre d'Investigation CLinique-Centre de Ressources Biologiques (CIC-CRB) 1404, Rouen, France. Electronic address: jeremy.bellien@chu-rouen.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Kidney Int</MedlineTA><NlmUniqueID>0323470</NlmUniqueID><ISSNLinking>0085-2538</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>87T4T8BO2E</RegistryNumber><NameOfSubstance UI="C047508">rotigotine</NameOfSubstance></Chemical><Chemical><RegistryNumber>137750-35-7</RegistryNumber><NameOfSubstance UI="D050641">Receptors, Dopamine D5</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0399OZS9N</RegistryNumber><NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016891" MajorTopicYN="Y">Polycystic Kidney, Autosomal Dominant</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="Y">Dopamine Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="Y">Nitric Oxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="Y">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013876" MajorTopicYN="Y">Thiophenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013764" MajorTopicYN="Y">Tetrahydronaphthalenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014664" MajorTopicYN="Y">Vasodilation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050641" MajorTopicYN="N">Receptors, Dopamine D5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autosomal dominant polycystic kidney disease</Keyword><Keyword MajorTopicYN="N">dopamine agonist</Keyword><Keyword MajorTopicYN="N">endothelium</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">nitric oxide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>1</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39216660</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2024.08.020</ArticleId><ArticleId IdType="pii">S0085-2538(24)00626-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>